Manacovid as an established effective COVID-19 treatment
01
What institutions accepted
The Democratic Republic of the Congo authorized Manacovid for market release and publicly treated reported results in 300 symptomatic SARS-CoV-2-positive patients as sufficient to present it as an effective, safe, and 100% curative COVID-19 treatment before publicly documented randomized evidence had established a treatment effect.
02
What the evidence supports now
Becoming test-negative and experiencing symptom resolution in a treated patient series do not by themselves show that a medicine caused recovery. The public reports of the 300 patients do not describe a randomized comparator, baseline severity, prespecified outcomes, or a transparent statistical analysis, leaving natural recovery, timing of testing, supportive treatment, and other differences as alternative explanations. A 2022 joint WHO, Africa CDC, and African Union mission that reviewed Manacovid among several Congolese traditional therapeutics concluded that the way the available data had been analyzed and presented had not generated the evidence needed to establish efficacy and recommended stronger observational and randomized trials. That was a portfolio-level assessment, not a negative product-specific randomized trial: it did not prove that Manacovid had no active ingredients or that it was unsafe, but it did mean the advertised therapeutic effect remained unestablished.
03
Evidence for the overall belief
Open sources, locators and notes
- DocumentsHistorical beliefLe ministre de la santé promet d’accompagner le pharmacien congolais géniteur du produit Manacovid lancé sur le marchéAgence Congolaise de Presse
Where in the source: 12 January 2021 report, paras. 1–6
The state news agency quotes the health minister's letter describing the investigators' results as conclusive and significant, promising directorate support so patients could find an effective and safe remedy, and stating that the ministry had authorized market release on 24 November 2020.
- DocumentsHistorical beliefLe MANACOVID, premier médicament curatif 100% efficace contre la COVID-19Agence Congolaise de Presse
Where in the source: Headline and opening three paragraphs
ACP called Manacovid the first 100%-effective curative COVID-19 medicine, said it had been launched on the market, and attributed a 100% recovery result in 300 patients to the principal investigator.
- DocumentsImpactHomologation en RDC d’un médicament anticovid dénommé « Manacovid »Agence Congolaise de Presse
Where in the source: 15 December 2020 report, paras. 1–6
Relaying a CRPL communiqué, ACP reports approval on 24 November 2020, 300 symptomatic positive cases becoming negative with symptom disappearance within five days, protocol approval by the national ethics committee, and clinical work conducted from June through October. It is evidence of the public account, not an independent audit of the study or the underlying authorization certificate.
- SupportsPresent correctionL’équipe conjointe d’experts (OMS, UA, CDC Afrique) salue les efforts de la République Démocratique du Congo en matière de recherche sur les traitements traditionnels de COVID19World Health Organization Regional Office for Africa
Where in the source: 31 March 2022 statement, paras. 2–13
The mission explicitly includes Manacovid among several products reviewed and says the way the data were analyzed and presented did not generate evidence of efficacy. Because the finding covers the reviewed portfolio, it is not treated here as a product-specific negative trial.
- SupportsPresent correctionExpert panel endorses protocol for COVID-19 herbal medicine clinical trialsWorld Health Organization Regional Office for Africa
Where in the source: 19 September 2020 release, paras. 1–8
The contemporaneous regional expert committee describes Phase III trials and independent data-safety monitoring as pivotal to establishing the quality, safety, and efficacy of herbal medical products before recommendation.
- DocumentsImpactLe ministre de la santé promet d’accompagner le pharmacien congolais géniteur du produit Manacovid lancé sur le marchéAgence Congolaise de Presse
Where in the source: 12 January 2021 report, quoted ministerial letter and final three paragraphs
Records both the ministry's supportive framing and the public account that all 300 symptomatic positive patients became test-negative after Manacovid, while mentioning antitussive or antipyretic treatment for residual symptoms.
04
Impact
Manacovid moved beyond an experimental candidate into authorized sale and official promotion. State reports said it received market authorization on 24 November 2020, repeated a claim that all 300 treated symptomatic patients became test-negative, and presented it as the first 100%-effective curative COVID-19 medicine. In January 2021 the health minister called the reported results conclusive and significant and promised ministry support toward an effective and safe remedy. Yet the Council of Ministers was still calling for randomization in September 2021, the joint expert mission found the presented evidence insufficient in March 2022, and a government research bulletin said in 2023 that Manacovid was still awaiting scientific proof at the University of Kinshasa Faculty of Medicine.
Context
The two authorization accounts are state-news reports, not the authorization certificate or a public clinical-study report. They document what the ministry, developer, and national press agency represented publicly; they do not independently verify the study design, individual outcomes, safety profile, or regulatory dossier.
The 2022 mission assessed a group of Congolese traditional COVID-19 therapeutics that included Manacovid. Its evidence finding should not be misrepresented as the result of a Manacovid-only randomized trial or as proof that every ingredient was inactive.
Manacovid does not appear by product or applicant name in ACOREP's public authorization register released in February 2026, although that register lists five later CRPL products. Absence from this register does not establish when or why the reported 2020 authorization expired, was withdrawn, or otherwise ceased to appear; no formal Manacovid withdrawal decision was located.
Reported date of authorization for market release as a COVID-19 treatment
Treated symptomatic patients publicly reported as all becoming test-negative
The public reports do not provide a comparator group or enough trial detail to attribute that outcome to Manacovid.
A government research bulletin said Manacovid was still awaiting scientific proof
Historical totals and effects are presented as contextual evidence, not as universal causal claims.
Institutional episode 01
Democratic Republic of the Congo
Central Africa
The Democratic Republic of the Congo gave Manacovid regulatory and political legitimacy before its claimed benefit had been demonstrated in a publicly documented randomized comparison. Authorization, a supportive ministerial letter, and emphatic reporting by the national press agency turned an incompletely reported 300-patient result into a marketable claim of safe and complete efficacy. Subsequent official actions reveal that the evidence remained unsettled: the cabinet sought randomization, an invited international mission found that the data presentation for the reviewed traditional therapeutics had not generated efficacy evidence, and the research minister later said Manacovid was still awaiting scientific proof.
Institutions involved
- Ministry of Public Health (later Ministry of Public Health, Hygiene and Prevention)
- Directorate of Pharmacy and Medicine
- Council of Ministers of the Democratic Republic of the Congo
- Ministry of Scientific Research and Technological Innovation
- Congolese Press Agency (ACP)
Institutional context
A December 2020 ACP report, relaying a communiqué from the private Luozi Pharmaceutical Research Centre, said that Manacovid had been approved on 24 November after work in 300 symptomatic patients and that its protocol had ethics approval. A January 2021 ACP report then quoted a health-minister letter calling the investigators' results conclusive and significant, promising support through the medicines directorate, and looking to Manacovid as an effective and safe remedy; the agency separately headlined it as the first 100%-effective curative medicine. In September 2021 the cabinet called for continued randomization of Manacovid toward international recognition. The health minister and other Congolese stakeholders received the joint expert mission's contrary evidentiary finding in March 2022. A July 2023 bulletin of the National Scientific Council and research ministry reported the research minister saying that Manacovid still awaited scientific proof at the University of Kinshasa.
Why this persisted
Administrative adoptionReported health-ministry authorization, support through the medicines directorate, national-press promotion, and cabinet sponsorship moved Manacovid from a privately developed candidate into the country's official treatment environment while confirmatory randomization was still being pursued.
How correction happened
Partially corrected2021–2023
Action: The cabinet called for randomization, the government received a joint expert review that found the presented data insufficient, and the research minister later said Manacovid still awaited scientific proof.
Congolese institutions participated in a meaningful evidentiary correction by pursuing randomized evaluation, hosting and receiving the 2022 expert mission, and later acknowledging that proof was still pending. The record does not show a product-specific randomized result, a retraction of the ministerial efficacy framing, a formal withdrawal decision, or an official account of how the reported 2020 authorization ended.
Consequences
- Authorization for market release and entry into the official pharmaceutical distribution environment
- State-news amplification of a 100% cure claim drawn from a reported 300-patient series
- Health-ministry support that publicly framed Manacovid as a prospective effective and safe remedy
- Cabinet-level pursuit of further randomization and international recognition after domestic authorization
- Continued evidentiary uncertainty acknowledged by government and international reviewers through 2023
Evidence for this episode
9 evidence linksOpen sources, locators and notes
- DocumentsInstitutional carrierLe ministre de la santé promet d’accompagner le pharmacien congolais géniteur du produit Manacovid lancé sur le marchéAgence Congolaise de Presse
Where in the source: Quoted letter from Health Minister Eteni Longondo
Connects the efficacy framing to the health minister and Directorate of Pharmacy and Medicine rather than only to the private product developer.
- DocumentsInstitutional carrierLe MANACOVID, premier médicament curatif 100% efficace contre la COVID-19Agence Congolaise de Presse
Where in the source: Headline and opening paragraphs
Documents amplification by the national press agency through an unqualified 100%-effective cure headline and announcement that the product had entered the market.
- DocumentsMechanismHomologation en RDC d’un médicament anticovid dénommé « Manacovid »Agence Congolaise de Presse
Where in the source: 15 December 2020 report, paras. 1–6
Describes the reported authorization and the sequence from government selection for trials through ethics approval, clinical work, and entry into the pharmaceutical market.
- DocumentsMechanismCompte rendu de la vingtième réunion du Conseil des Ministres du 17 septembre 2021Primature de la République Démocratique du Congo
Where in the source: Section II.3, p. 6
Official cabinet minutes place Manacovid on the national research agenda by calling for continued randomization toward international recognition as a COVID-19 treatment.
- DocumentsConsequencesLe MANACOVID, premier médicament curatif 100% efficace contre la COVID-19Agence Congolaise de Presse
Where in the source: Headline and opening three paragraphs
- DocumentsInstitutional correctionCompte rendu de la 20e réunion du Conseil des ministres du 17 septembre 2021Primature de la République Démocratique du Congo
Where in the source: Section II.3, p. 6
The current official archive page supplies an accessible copy of the minutes. Their call for randomization shows that confirmatory evidence was still being pursued after domestic authorization; the minutes frame that work as a route to international recognition rather than retracting the domestic claims.
- DocumentsInstitutional correctionL’équipe conjointe d’experts (OMS, UA, CDC Afrique) salue les efforts de la République Démocratique du Congo en matière de recherche sur les traitements traditionnels de COVID19World Health Organization Regional Office for Africa
Where in the source: 31 March 2022 statement, paras. 2–13
Records restitution of the mission's findings to the health minister and other stakeholders, continued technical assistance, and recommendations for stronger observational and randomized protocols and regulatory oversight.
- DocumentsInstitutional correctionBulletin Sciences et Innovations Technologiques — N°009, juillet 2023National Scientific Council, Ministry of Scientific Research and Technological Innovation
Where in the source: Bulletin p. 3, report of the research minister's June 2023 press conference
The ministry and National Scientific Council bulletin reports Research Minister Gilbert Kabanda saying Manacovid was awaiting scientific proof at the University of Kinshasa Faculty of Medicine, an official acknowledgment that the efficacy question remained unresolved.
- ContextualizesContextRépertoire des Autorisations de Mise sur le MarchéCongolese Pharmaceutical Regulatory Authority (ACOREP)
Where in the source: Entire register; CRPL entries 5358–5361 and 5469
The register released on 4 February 2026 contains no Manacovid or COVID treatment entry under CRPL, while listing five CRPL registrations issued in 2025 for Manalaria, Manadiar, and EVA. A missing entry cannot establish the legal route or date by which the reported 2020 authorization ended, so it is not treated as proof of formal withdrawal.
Source registryEach source is registered once and can carry several precise evidence relationships.9 sources
- 013 evidence links
- 02Le MANACOVID, premier médicament curatif 100% efficace contre la COVID-19Agence Congolaise de Presse3 evidence links
- 03Compte rendu de la vingtième réunion du Conseil des Ministres du 17 septembre 2021Primature de la République Démocratique du Congo1 evidence link
- 04Compte rendu de la 20e réunion du Conseil des ministres du 17 septembre 2021Primature de la République Démocratique du Congo1 evidence link
- 05L’équipe conjointe d’experts (OMS, UA, CDC Afrique) salue les efforts de la République Démocratique du Congo en matière de recherche sur les traitements traditionnels de COVID19World Health Organization Regional Office for Africa2 evidence links
- 06Homologation en RDC d’un médicament anticovid dénommé « Manacovid »Agence Congolaise de Presse2 evidence links
- 07Expert panel endorses protocol for COVID-19 herbal medicine clinical trialsWorld Health Organization Regional Office for Africa1 evidence link
- 08Bulletin Sciences et Innovations Technologiques — N°009, juillet 2023National Scientific Council, Ministry of Scientific Research and Technological Innovation1 evidence link
- 09Répertoire des Autorisations de Mise sur le MarchéCongolese Pharmaceutical Regulatory Authority (ACOREP)1 evidence link